TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has active Crohn's disease with a score on the Crohn's disease activity index between 220 and 450 points.~* Patient has active Ulcerative colitis as defined by a total Mayo score between 6 and 12 points (Part 2 only).~Exclusion Criteria:~* Patient who has previously received a biological agent for the treatment of CD and UC and/or a tumor necrosis factor-alpha (TNFα) inhibitor for the treatment of other disease~* Patient who has allergies to any of the excipients of infliximab or any other murine and/or human proteins or patient with a hypersensitivity to immunoglobulin product~* Patient who has a current or past history of infection with HIV, hepatitis B, or hepatitis C (carriers of hepatitis B and hepatitis C are not permitted to enrol into the study, but past hepatitis B resolved can be enrolled)~* Patient who has acute infection requiring oral antibiotics within 2 weeks or parenteral injection of antibiotics within 4 weeks prior to the first administration of the study drug, other serious infection within 6 months prior to the first administration of study drug or recurrent herpes zoster or other chronic or recurrent infection within 6 weeks prior to the first administration of the study drug~* Patient who has an indeterminate result for interferon-γ release assay (IGRA) or latent tuberculosis (TB) at Screening. For Part 2, if IGRA result is indeterminate at Screening, 1 retest will be possible during the screening. If the repeated IGRA result is negative, the patient can be included in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: CT-P13 IV 5 mg/kg (Type: ACTIVE_COMPARATOR): CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks (Part 1)
- Cohort 2: CT-P13 SC 120 mg (Type: EXPERIMENTAL): CT-P13 SC (Infliximab), 120 mg by SC injection every 2 weeks (Part 1)
- Cohort 3: CT-P13 SC 180 mg (Type: EXPERIMENTAL): CT-P13 SC (Infliximab), 180 mg by SC injection every 2 weeks (Part 1)
- Cohort 4: CT-P13 SC 240 mg (Type: EXPERIMENTAL): CT-P13 SC (Infliximab), 240 mg by SC injection every 2 weeks (Part 1)
- Arm 1: CT-P13 SC 120/240 mg (Type: EXPERIMENTAL): CT-P13 SC (Infliximab), either 120 mg or 240 mg every 2 weeks by SC injection (Part 2)
- Arm 2: CT-P13 IV 5 mg/kg (Type: ACTIVE_COMPARATOR): CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks up to Week 22. CT-P13 IV was switched to either 120 mg or 240 mg of CT-P13 SC (Infliximab) treatment, and further doses with CT-P13 SC were given up to Week 54. (Part 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients \> 45 years~* Damage of the optic nerve and alterations of the visual field in case of POAG, no defects at the optic nerve and at the visual field in case of OHT~* Untreated IOP \> 24 mm Hg but \< 32 mm Hg in at least one eye at baseline (10AM) and central corneal thickness between 500 and 600 μm~* Negative pregnancy test (fertile women). Fertile women attending the study must express clear will to avoid pregnancy during all the study period and in the next three months~* Informed consent before starting the study~Exclusion Criteria:~* Secondary glaucoma (Sturge-Weber syndrome, Neurofibromatosis I, neovascular glaucoma, steroid glaucoma, etc)~* Anterior segment anomalies (cataract, irido-corneal disgenesy, congenital ectropion uvae, etc)~* Past ocular surgery, except cataract surgery in the previous 6 months~* Corneal abnormalities that can influence IOP measurements (corneal oedema)~* Positive pregnancy test or breast-feeding woman. No will to avoid pregnancy during all the study period and in the next three months

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAFLUPROST 0.0015% EYEDROPS (Type: EXPERIMENTAL): Tafluprost 0.0015% preservative-free ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means of Goldmann and Perkins applanation tonometry.
- LATANOPROST 0.005% EYEDROPS (Type: ACTIVE_COMPARATOR): Latanoprost 0.005% preservative-added ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means Goldmann and Perkins applanation tonometry.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Indication of revascularization~* De novo lesions~* Native vessels~* Suitable for stent placement~Exclusion Criteria:~* Acute myocardial infarction within the last 24 hours~* In stent restenosis~* Previous percutaneous coronary intervention within the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A--Oral Rapamycin plus BMS (Type: EXPERIMENTAL): Oral sirolimus plus bare metal stent implantation
- B -- Drug Eluting Stent (Type: ACTIVE_COMPARATOR): Drug Eluting Stents

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient aged 65 and older~* Patient with mono/polyarticular CPPD acute arthritis~* Hospitalized patient (without infectious syndrome considered insufficiently controlled by the clinicians and diabetic decompensation)~* Diagnosis confirmed :~* By the evidence of CPP crystals on synovial fluid examination.~* By the existence of a typical clinical arthritis (joint pain, erythema, swelling, maximal intensity in less than 24h) AND presence of chondrocalcinosis signs in knee, wrists, or pubic symphysis on plain X-rays or crowned tooth in cervical rachis scan.~* Pain VAS ≥ 40/100 at the enrollment~* Duration of symptoms evolution for less than 36h.~* No prior intake of oral steroids, colchicine or NSAIDs for this acute arthritis.~* Signed patient's consent.~* Affiliation to a social security scheme.~Exclusion Criteria:~* Contraindication to colchicine (creatinine clearance below 30ml/min, severe hepatic dysfunction, macrolide or ongoing pristinamycin or macrolid treatment, ...) or corticoids utilization (uncontrolled diabetes, uncontrolled progressive infection, uncontrolled arterial hypertension...)~* Severe cognitive disorders that does not allow patient to evaluate his pain.~* Patient under guardianship, curatorship~* Patient receiving morphinic analgesia.~* Gout history or presence of monosodium urate crystals at the examination of the synovial fluid.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Colchicine (Type: ACTIVE_COMPARATOR): Patients assigned to this group will receive the Colchicine opocalcium 1mg treatment.
- Prednisone (corticoids) (Type: EXPERIMENTAL): Patients assigned to this group will receive Prednisone : Cortancyl 20mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Intravenous Antibiotics In Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neonates (≥ 35+0 weeks, 0-28 days old, ≥ 2 kg)~* Probable bacterial infection defined as clinical symptoms and/or maternal risk factors and elevated inflammatory markers for which empiric broad-spectrum antibiotic treatment was initiated and needs to be continued for \> 48 hours~* Clinically well~* Toleration of oral feeding without overt vomiting~* Signed informed consent~Exclusion Criteria:~* Proven bloodstream infection~* Absence of blood culture~* Severe localized infection (meningitis, osteomyelitis, necrotizing enterocolitis)~* Severe clinical sepsis (compromised circulation, need for mechanical ventilation)~* Continuous need for a central venous line~* Severe hyperbilirubinemia exceeding the exchange level~* Parents inability to administer medication~* Major congenital or syndromic anomalies

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Oral group (Type: ACTIVE_COMPARATOR): After 48 hours of intravenous antibiotics eligible neonates will switch to amoxicillin/clavulanic acid suspension for the remaining 5 days. When the oral suspension is well tolerated neonates can be discharged from hospital.~In order to investigate the pharmacokinetic profile of oral amoxicillin/clavulanic acid serum levels will be measured.
- Intravenous group (Type: ACTIVE_COMPARATOR): Neonates will complete the full course of antibiotics of 7 days intravenously in hospital following local protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent,~* 30 to 85 years old,~* Plan to undergo PCI and LDL-C \>= 100 mg/dL~Exclusion Criteria:~* Familial hypercholesterolemia~* Being treated with Zetia (Ezetimibe)~* Being treated with Fibrates~* Renal insufficiency (serum creatinine \>= 2.0 mg/dl)~* Altered hepatic function (serum aspartate aminotransferase or alanine aminotransferase \>= 3-folds of standard value in each institute)~* Undergoing hemodialysis or peritoneal dialysis~* Allergic to Lipitor and/or Zetia~* Severe underlying disease~* Lack of decision-making capacity~* Recognized as inadequate by attending doctor

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- LZ group (Type: EXPERIMENTAL): None
- L group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Febuxostat Versus Allopurinol Control Trial in Subjects With Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meeting the preliminary criteria of the American Rheumatism Association for the classification of the acute arthritis of primary gout.~* Serum uric acid ≥ 8.0 milligrams per deciliter (mg/dL) at Baseline~Exclusion Criteria:~* Serum creatinine \>1.5 mg/dL~* Calculated creatinine clearance of \<50 milliliters per minutes (mL/min)~* Pregnancy or lactation;~* Concurrent therapy with urate lowering agents, azathioprine, 6-mercaptopurine, thiazide diuretics, or medications containing aspirin (\>325 mg) or other salicylates;~* Body Mass Index (BMI) \>50 kilogram per meter²(kg/m²);~* A history of xanthinuria, active liver disease, or hepatic dysfunction;~* A history of alcohol abuse or intake of 14 or more alcohol-containing drinks/week.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Febuxostat 80 mg QD (Type: EXPERIMENTAL): None
- Febuxostat 120 mg QD (Type: EXPERIMENTAL): None
- Allopurinol 300 mg QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female subjects, aged 18 - 30 years~* Signed informed consent after being advised of the risks and benefits of the study in a language able to understand, and prior to performance of any study specific procedure.~* Free of obvious health problems with acceptable medical history by screening evaluation and physical examination.~* Subject of not of child-bearing potential or all of the following: A urine/serum ß-HCG pregnancy test gives a negative result, use of adequate contraceptive precautions for 30 days before first vaccination.~Exclusion Criteria:~* Known or suspected history of smallpox vaccination or typical vaccinia scar.~* Positive test result in MVA specific ELISA or PRNT at screening.~* Positive result in HIV or HCV antibody test at screening.~* HbsAG positive at screening.~* Pregnancy or breast-feeding.~* Uncontrolled serious infection i.e. not responding to antimicrobial therapy~* History of any serious medical condition, which in the opinion of the investigator, would compromise the safety of the subject.~* History of autoimmune disease~* History of malignancy.~* History of chronic alcohol abuse and/or intravenous drug abuse.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* History of anaphylaxis or severe allergic reaction.~* Acute disease (a moderate or severe illness with or without a fever) at the time of enrolment.~* Any vaccinations within a period starting 30 days prior to administration of the vaccine and ending at study conclusion.~* Chronic administration of immuno-suppressants or other immune-modifying drugs.~* Administration or planned administration of immunoglobulins and/or any blood products during the study period.~* Use of any investigational or non-registered drug or vaccine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): healthy, vaccinia naïve subjects 2 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
- Group 2 (Type: ACTIVE_COMPARATOR): healthy, vaccinia naïve subjects 5 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
- Group 3 (Type: ACTIVE_COMPARATOR): healthy, vaccinia naïve subjects~1 x 10E8 TCID50 IMVAMUNE (MVA-BN), subcutaneous

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Clinical Efficacy of Three Oral Hygiene Regimens Using a Manual Toothbrush, Toothpaste and a Mouthwash in Controlling Dental Plaque and Gingivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects, ages 21-70, inclusive.~2. Availability for the six-week duration of the study.~3. Good general health.~4. Minimum of 20 uncrowned permanent natural teeth (excluding third molars).~5. Initial gingivitis index of at least 1.0 as determined by the use of the Loe and Silness Gingival Index.~6. Initial plaque index of at least 1.5 as determined by the use of the Quigley and Hein Plaque Index (Turesky Modification).~7. Signed Informed Consent Form.~Exclusion Criteria:~1. Presence of orthodontic bands.~2. Presence of partial removable dentures.~3. Tumor(s) of the soft or hard tissues of the oral cavity.~4. Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone).~5. Five or more carious lesions requiring immediate restorative treatment.~6. Use of antibiotics any time during the one month prior to entry into the study.~7. Participation in any other clinical study or test panel within the one month prior to entry into the study.~8. Pregnant women or women who are breast feeding.~9. Dental prophylaxis received in the past two weeks prior to baseline examinations.~10. History of allergies to oral care/personal care consumer products or their ingredients.~11. On any prescription medicines that might interfere with the study outcome.~12. An existing medical condition which prohibits eating or drinking for periods up to 4 hours.~13. History of alcohol or drug abuse

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Regimen 1 (Type: ACTIVE_COMPARATOR): triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash
- Regimen 2 (Type: ACTIVE_COMPARATOR): stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
- Regimen 3 - Control group (Type: PLACEBO_COMPARATOR): fluoride toothpaste + fluoride Mouthwash

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Lower Grade Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be able to provide a written informed consent~* suspected lower grade gliomas on contrast-enhanced MRI~Exclusion Criteria:~* Consisted of conditions of mental illness~* Severe liver or kidney disease with serum creatinine \> 3.0 mg/dl (270 μΜ)~* Any hepatic enzyme level 5 times or more than normal upper limit~* Severe allergy or hypersensitivity to IV radiographic contrast~* Claustrophobia to accept the PET/CT or PET/MRI scanning~* Pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 68Ga-BBN-IRDye800CW PET/NIRF (Type: EXPERIMENTAL): The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 or 2.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient must fulfill El Escorial criteria (APPENDIX 2) for definite or probable ALS (sporadic and not familial)~2. Participants, either men or non pregnant women are between 20 and 75 years of age.~3. The patient is mentally intact and psychologically stable~4. Patients will be with an ALS-FRS-R scale (APPENDIX 3) of at least 30 and disease duration of less than 2 years.~5. Patient has sufficiently bulky muscles.~6. Participant understands the nature of the procedure and provides written informed consent prior to any study procedure.~Exclusion Criteria:~1. Patient has a positive test for HBV, HCV or HIV.~2. Patient has high protein in the CSF (Protein \> 70 mg/ml).~3. Patient has lymphocytosis in the CSF (lymphocytes \> 5/ml).~4. Patient is positive for anti-GM1 antibodies.~5. Patient has significant conduction blocks or slow nerve conduction velocities (a reduction of more than 30%) confirmed by nerve conduction velocity - EMG studies.~6. The patient is a respiratory dependent patient.~7. Patients with renal failure (Cr \> 2 mg/dl).~8. Patients with impaired hepatic function (ALT, AST or GGT 2-fold higher than normal upper limit).~9. Patients suffering from significant cardiac disease, malignant disease or any other disease that may risk the patient or interfere with the ability to interpret the results~10. Patient with active infections.~11. Participation in another clinical trial within 1 month prior to start of this study.~12. Patient has not been treated previously with any cellular therapy.~13. Subject unwilling or unable to comply with the requirements of the protocol.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MSC-NTF (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete